How We Help
NET Cancer is the FASTEST growing class of CANCER worldwide
HELP US HELP OTHERSNeuroendocrine Tumours (NETs) Overview
- Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
- NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
- NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
- NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
- The cause of NETs is currently unknown.
Contact Us For Live Support
Support Lines:
416-628-3189
Toll Free: 1-844-628-6788
Latest CNETS Canada News
Public Listings for Caprelsa
Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the listing on their Outpatient Cancer [...]
Patient Input – Treatment with Telotristat
TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat has applied to Health Canada [...]
A Common Classification Framework For Neuroendocrine Neoplasms
RESEARCH ARTICLE A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal Published in Modern Pathology - August 23, 2018 [...]
ARETHA FRANKLIN DIED FROM NEUROENDOCRINE CANCER
RIP THE GREAT ARETHA FRANKLIN Aretha Franklin, the Queen of Soul, passed away from neuroendocrine cancer (NETs) of the pancreas, the very same cancer that killed Apple founder Steve Jobs. Confirmed in [...]
NET Research Priorities Survey Results
In March CNETS Canada reached out to the patient community through an online, anonymous survey to gather feedback and input on setting the research priorities for CNETS Canada sponsored grants for the next 2-3 years. [...]
Patient Input – Treatment with Lutetium-177 (177Lu)-DOTATATE
REQUEST FOR PATIENT INPUT - TREATMENT WITH Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera) Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera), is a peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues (peptides). Lutetium-177 (177Lu)-DOTATATE treatment was approved last year [...]